Rituximab/hyaluronidase

Drug Profile

Rituximab/hyaluronidase

Alternative Names: MabThera SC; Rituxan Hycela; RITUXAN SC; Rituximab subcutaneous

Latest Information Update: 19 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Roche
  • Developer Halozyme Therapeutics; Roche
  • Class Antineoplastics; Glycoside hydrolases; Monoclonal antibodies; Polysaccharide lyases
  • Mechanism of Action Cell death stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma

Most Recent Events

  • 23 Jun 2017 Launched for Chronic lymphocytic leukaemia (Combination therapy, First-line therapy, Second-line therapy or greater) in USA (SC)
  • 23 Jun 2017 Launched for Diffuse large B cell lymphoma (First-line therapy, Combination therapy) in USA (SC)
  • 23 Jun 2017 Launched for Follicular lymphoma (First-line therapy, Second-line therapy or greater) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top